文献速递肝胆胰外科围术期管理与 ERAS

机器人辅助微创胰十二指肠切除术的围术期与肿瘤学结局:基于胰瘘风险评分及癌症分期匹配与开放手术的比较

Perioperative and oncologic outcome of robot-assisted minimally invasive (hybrid laparoscopic and robotic) pancreatoduodenectomy: based on pancreatic fistula risk score and cancer/staging matched comparison with open pancreatoduodenectomy.
PubMed 文献 · Surg Endosc · 2020-04-10

本研究比较了150例机器人辅助微创(混合腹腔镜与机器人)胰十二指肠切除术(RA-MIPD)与710例开放胰十二指肠切除术(PD)的围术期及肿瘤学结局。倾向性评分匹配后,RA-MIPD组手术时间更长,但总体并发症和临床相关术后胰瘘(CR-POPF)率相似,疼痛评分更低、术后住院时间更短。在恶性肿瘤患者中按癌症和分期匹配后,R0切除率、肿瘤大小、淋巴结检出数和2年生存率均无显著差异。结论认为RA-MIPD安全可行,围术期结局优于或至少不劣于开放手术,中期生存结局相当。

要点

  • RA-MIPD与开放PD的总体并发症和CR-POPF率相似。
  • RA-MIPD术后疼痛评分更低,住院时间更短(11.5 vs. 17.2天)。
  • 恶性肿瘤患者中R0切除率、淋巴结检出数和2年生存率无显著差异。

核心结论

  • 与开放PD相比,RA-MIPD具有更好或至少相似的早期围术期结局和等效的中期生存结局。
  • RA-MIPD安全可行,有助于术后早期恢复。

研究设计与样本

  • 回顾性比较研究,纳入2015至2018年150例RA-MIPD患者与710例开放PD患者。
  • 采用倾向性评分匹配(PSM)分析,基于胰瘘风险匹配评估并发症,并按癌症和分期匹配评估恶性肿瘤患者的肿瘤学结局。

主要发现

  • RA-MIPD组年龄更轻(61.2 vs. 65.5岁,P < 0.001),性别(P = 0.091)和BMI(P = 0.281)无显著差异。
  • RA-MIPD组手术时间更长(361.2 vs. 305.7 min,P < 0.001),估计出血量无显著差异(515.6 vs. 478.0 mL,P = 0.318)。
  • 总体并发症(24.7% vs. 30.9%,P = 0.178)和CR-POPF率(6.7% vs. 6.9%,P > 0.999)相似。
  • RA-MIPD组疼痛评分更低,术后住院时间更短(11.5 vs. 17.2天,P < 0.001)。
  • 恶性肿瘤患者匹配后,R0切除率(96.7% vs. 93.3%,P = 0.527)、肿瘤大小(2.59 vs. 2.60 cm,P = 0.954)、淋巴结检出数(17.0 vs. 16.6,P = 0.793)和2年生存率(84.4% vs. 77.8%,P = 0.898)无显著差异。

临床怎么用

  • RA-MIPD可作为开放PD的可行替代,尤其适用于期望微创恢复的患者。
  • 需基于胰瘘风险评分评估CR-POPF风险,并关注手术时间延长的影响。

局限性

  • 回顾性研究设计,可能存在选择偏倚。
  • RA-MIPD组患者更年轻,可能影响围术期结局比较。
  • 中期生存随访时间有限,长期肿瘤学结局需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robotic surgery is a novel approach that scores over conventional minimally invasive approaches, even in pancreatic surgery. We investigated clinical outcomes of robot-assisted minimally invasive (hybrid laparoscopic and robotic) pancreatoduodenectomy (RA-MIPD). METHODS: Total 150 patients who underwent RA-MIPD between 2015 and 2018 were compared with 710 patients who underwent open pancreatoduodenectomy (PD) during the same period. Demographics and surgical outcomes were analyzed, and propensity score-matched (PSM) analysis was performed to evaluate complications including clinically relevant postoperative pancreatic fistula (CR-POPF) and oncologic outcomes in patients with malignancy. RESULTS: PSM analysis was performed based on the pancreatic fistula risk. Patients undergoing RA-MIPD were younger (RA-MIPD vs. open PD: 61.2 vs. 65.5 years, P < 0.001); however, no significant intergroup difference was observed in sex (P = 0.091) and body mass index (P = 0.281). Operation time was longer in the RA-MIPD group (361.2 vs. 305.7 min, P < 0.001); however, estimated blood loss did not significantly differ (515.6 vs. 478.0 mL, P = 0.318). Overall complication (24.7% vs. 30.9%, P = 0.178) and CR-POPF rates (6.7% vs. 6.9%, P > 0.999) were similar. The RA-MIPD group showed lower pain scores and shorter length of postoperative hospitalization (11.5 vs. 17.2 days, P < 0.001). After PSM analysis for cancer and staging among patients with malignancies, no significant intergroup difference was observed in the R0 resection rate (96.7% vs. 93.3%, P = 0.527), tumor size (2.59 vs. 2.60 cm, P = 0.954), total number of retrieved lymph nodes (17.0 vs. 16.6, P = 0.793), and 2-year survival rates (84.4% vs. 77.8%, P = 0.898). CONCLUSIONS: Compared with open PD, RA-MIPD is associated with better or at least similar early perioperative and equivalent midterm survival outcomes. RA-MIPD is safe and feasible and enables early postoperative recovery. RA-MIPD is expected to play a key role in near future.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Kim HS, Kim H, Kwon W, et al. Perioperative and oncologic outcome of robot-assisted minimally invasive (hybrid laparoscopic and robotic) pancreatoduodenectomy: based on pancreatic fistula risk score and cancer/staging matched comparison with open pancreatoduodenectomy. Surg Endosc. 2020. PMID: 32277354. doi:10.1007/s00464-020-07551-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。